Pieter Cullis

Professor

mail pieterc@mail.ubc.ca

call 604-827-0347

location_on 5451

open_in_new Lab Website

open_in_new Publications

Research Focus Teams

COVID-19, Cancer, Diabetes

Research Interests

Auto-Immune Diseases, Cell Therapy of Cancer, Chemotherapy, Gene Therapy of Cancer, Vaccine and Cancer, Nanomedicine

Departments

Biochemistry & Molecular Biology

Bio

Dr. Pieter Cullis OC, former Director of the Life Sciences Institute, is a Professor in the Department of Biochemistry and Molecular Biology at UBC. He is recognized for making fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule drugs and genetic drugs. These efforts have led to 5 approved LNP drugs (Abelcet, Myocet, Marqibo, Onpattro and Comirnaty). Dr. Cullis has co-founded and served on the board of more than 10 companies to commercialize his research in nanomedicines. These include the Canadian Liposome Company, Inex Pharmaceuticals (now Arbutus Biopharma), Northern Lipids Inc. (now Evonik Canada), Acuitas Therapeutics and Precision NanoSystems. He also founded and led pan-Canada research centres including the Centre for Drug Research and Development (CDRD; 2004-2010), and NanoMedicines Innovation Network (NMIN; 2019-2021) to advance academic research, commercialization and training of the next generation scientists. Dr. Cullis has received many awards throughout his career; notably in 2021-2022 for his contribution in the Covid-19 vaccine, he was awarded Prince Mahidol Award, VinFuture Prize Grand Prize, Canada Gairdner International Award and Governor General's Innovation Award. Dr. Cullis is an Officer of the Royal Society of Canada. He has published over 380 papers and holds 80 patents.

Recent Publications

chevron_left
chevron_right

RNA lipid nanoparticles stabilized during nebulization through excipient selection

Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community

Liposomal lipid nanoparticles for extrahepatic delivery of mRNA

Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels

Protein is expressed in all major organs after intravenous infusion of mRNA-lipid nanoparticles in swine.

Quantitative Visualization of Lipid Nanoparticle Fusion as a Function of Formulation and Process Parameters

siRNA-mediated reduction of a circulating protein in swine using lipid nanoparticles

Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions

A magnetic separation method for isolating and characterizing the biomolecular corona of lipid nanoparticles

Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A

Determination of the interior pH of lipid nanoparticles using a pH-sensitive fluorescent dye-based DNA probe

Single Pulse Nanosecond Laser-Stimulated Targeted Delivery of Anti-Cancer Drugs from Hybrid Lipid Nanoparticles Containing 5 nm Gold Nanoparticles

Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human Skin

Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues

Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency

Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles

Morphological Behavior of Liposomes and Lipid Nanoparticles

On the Influence of Nucleic Acid Backbone Modifications on Lipid Nanoparticle Morphology

Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy

Lipid Nanoparticle Mediated Silencing of Osteogenic Suppressor GNAS Leads to Osteogenic Differentiation of Mesenchymal Stem Cells In Vivo

Synthesis and Characterization of Hybrid Lipid Nanoparticles Containing Gold Nanoparticles and a Weak Base Drug

Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Suppression of fibrin(ogen)-driven pathologies through controlled knockdown by lipid nanoparticle delivery of siRNA